Talk Bio

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

Lilly reports new Phase 1b data on PCSK9 base‑editing gene therapy from Verve buyout

Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances

Merck’s Oral PCSK9 Inhibitor Enlicitide Decanoate Achieves Third Consecutive Phase 3 Success